NGS is suitable for almost all of mutations appearing in the NSCLC, such as EGFR, RET, MET, ALK, HER2, BRAF, ROS1, KRAS, and NTRK, also including some new biomarkers such as PIK3CA (103). This evidence concerns the gene ROS1 and non-small cell lung carcinoma.